PLx Pharma (FRA:1D5A) Capex-to-Operating-Income : 0.00 (As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

PLx Pharma's Capital Expenditure for the three months ended in Sep. 2022 was €0.00 Mil. Its Operating Income for the three months ended in Sep. 2022 was €-10.95 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

PLx Pharma Capex-to-Operating-Income Historical Data

The historical data trend for PLx Pharma's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Capex-to-Operating-Income Chart

PLx Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Capex-to-Operating-Income

Get a 7-Day Free Trial

PLx Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Capex-to-Operating-Income	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of PLx Pharma's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PLx Pharma's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PLx Pharma's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where PLx Pharma's Capex-to-Operating-Income falls into.

PLx Pharma Capex-to-Operating-Income Calculation

PLx Pharma's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2021 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	-36.099
	=	N/A

PLx Pharma's Capex-to-Operating-Income for the quarter that ended in Sep. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	-10.947
	=	N/A

PLx Pharma (FRA:1D5A) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

PLx Pharma Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of PLx Pharma's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

PLx Pharma (FRA:1D5A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Inc (FRA:1D5A) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 The Green, Suite 11895, Dover, DE, USA, 19901

Website

https://www.plxpharma.com

PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

PLx Pharma (FRA:1D5A) Headlines

No Headlines